Mounjaro Classification: What Drug Class Is Tirzepatide? (October 2026)

01 · The core answer

What is the classification for Mounjaro?

Mounjaro has a pharmacological class, a legal status and a clinical purpose. Its class is dual GIP and GLP-1 receptor agonist. Its legal status is prescription-only medicine. Its purpose, in the UK, is weight management in adults and type 2 diabetes¹.

The active ingredient is tirzepatide, a synthetic peptide. Mounjaro is the brand name used by Eli Lilly. Pharmacists and prescribers may write either name; they refer to the same medicine. Tirzepatide is described as the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1¹.

You may be looking for a classification such as a tier, schedule or category. In the UK, there is no tier system for prescribing. The thing that matters legally is that Mounjaro is prescription-only, so it can be supplied only after a consultation reviewed by a GPhC-registered prescriber. Anyone offering to supply it without a consultation or prescription is not operating legitimately.

02 · Quick reference

The classification in a table

03 · What to do next

Is this relevant to you, and what next?

If you are considering treatment, the licensed use matters most. It is used alongside a reduced-calorie diet and increased physical activity, and individual results vary. Our weight loss clinic explains who treatment suits.

Ready readers can start a free consultation on the Mounjaro pen page. A GPhC-registered prescriber reviews every order, and unsuitable orders are refunded automatically.

04 · What the class names mean

What the words in the classification mean

The classification looks technical, but each term is simple. A receptor is a docking point on a cell. An agonist is a medicine that activates that docking point, mimicking a natural signal. So a GIP and GLP-1 receptor agonist copies two natural gut hormones. Those hormones are released after eating and help regulate appetite, digestion and blood sugar¹.

GIP stands for glucose-dependent insulinotropic polypeptide. GLP-1 stands for glucagon-like peptide-1. Both belong to a family called incretins, hormones that respond to food. That is why you may see Mounjaro described as an incretin-based therapy or an incretin mimetic. The words all point to the same idea: the medicine works by imitating hormones the gut already makes.

The term dual matters. Many earlier medicines in this area acted on the GLP-1 receptor only. Tirzepatide acts on GIP and GLP-1 together. Some writers call it a twincretin, a shorthand for a medicine combining two incretin actions in a single molecule. It is not two separate drugs in one pen. It is one active ingredient with a dual action.

Tirzepatide is also a peptide, meaning a short chain of amino acids. Mounjaro is given by injection under the skin; there is no tablet form of Mounjaro, as tirzepatide is injection-only in the UK. The pen is a pre-filled multi-dose KwikPen, and the dose is taken once a week. For the physical makeup of the pen, see our guide to Mounjaro components.

Classification can also refer to a treatment category in the BNF, the prescribing reference used by UK clinicians¹¹. The BNF lists tirzepatide with its indications, dosing and safety information. If you want the regulatory paperwork behind the medicine, our page on the Mounjaro EPAR explains where the assessment documents sit.

One more distinction is worth making. Class describes how a medicine acts. It does not tell you how strong it is, how safe it is for you, or whether you qualify. Those questions need an individual assessment, which is why a prescriber reviews every consultation rather than relying only on a category name.

05 · How the dual action works

How a dual GIP and GLP-1 agonist works

The class name describes the mechanism, so it helps to see what the two actions do together. Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin¹.

In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet. That last phrase is important. The medicine is not a substitute for eating differently or moving more. It makes a reduced-calorie diet easier to follow for many people, but it is used alongside lifestyle changes, not instead of them.

Slower stomach emptying is one reason the digestive system is where many people notice effects first. The patient information leaflet lists the side effects and explains what to do about them¹³. Your prescriber can talk through anything that concerns you.

You may wonder whether Mounjaro is a diuretic or a fat-burning drug. Neither term is its classification. A diuretic increases urine output, and that is not how tirzepatide is classed. Our short guide on whether Mounjaro is a diuretic goes into it. Likewise, descriptions such as lipolysis belong to a different conversation; see our page on Mounjaro and lipolysis.

Duration matters in mechanism too. Tirzepatide has a half-life of about five days, so after a final dose it takes roughly 4–5 weeks to clear the system — there is no way to speed this up, and nothing needs doing while it clears. That long clearance is part of why a once-weekly schedule is possible.

Your own response will depend on dose, diet, activity, health and time on treatment.

Finally, the mechanism is why the class label is not a marketing flourish. When people say Mounjaro is different from single-action GLP-1 medicines, they are pointing at the dual receptor activity. Whether that difference matters for a particular person is a conversation for a prescriber, not a label.

06 · Mounjaro versus Ozempic class

What classification is Ozempic, and how does it differ?

Ozempic and Wegovy contain semaglutide, which is a single-action GLP-1 receptor agonist. Mounjaro contains tirzepatide, which acts on GIP and GLP-1 together. This dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide (Wegovy/Ozempic)¹.

So the broad family is shared. Both are injectable, once-weekly, prescription-only medicines that act on gut-hormone pathways. The narrower class differs. Calling Ozempic a GLP-1 medicine is correct. Calling Mounjaro a GLP-1 medicine is partly correct, but incomplete, because it also activates the GIP receptor. This is why the answer to “Is Mounjaro a GLP-1?” is: it activates the GLP-1 receptor, and a second one as well.

Brand names add confusion. Wegovy and Ozempic share an active ingredient but are licensed for different purposes: Ozempic is semaglutide licensed for type 2 diabetes and is not a UK weight-loss medicine, while Wegovy (semaglutide 2.4mg) is licensed for weight management. The Wegovy label sets out a dose ladder of 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg, stepping up after at least four weeks, reaching 2.4mg as the maintenance dose for weight management¹⁸. Mounjaro uses its own strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.

Do not read strengths across products. A milligram of one medicine is not equivalent to a milligram of another, because they are different molecules. A number on one pen says nothing about the number on another.

Which is safer? No class label answers that. Both are licensed medicines with their own leaflets and risks. The first large trial that directly compares tirzepatide with semaglutide for obesity is SURMOUNT-5¹⁵.

Liraglutide, found in Saxenda, is another GLP-1 medicine. It is supplied at 6mg per millilitre and is a daily injection, unlike once-weekly Mounjaro and Wegovy.

The practical lesson: classification tells you family and mechanism. Choice between medicines depends on your health, history, goals, tolerance and what a prescriber judges appropriate. Our weight loss clinic page covers the wider options.

07 · Legal status and tiers

Legal status: prescription-only, not a tier

In the UK, Mounjaro is a prescription-only medicine. That means it is supplied only after an online consultation reviewed by a GPhC-registered prescriber. It is used alongside a reduced-calorie diet and increased physical activity. Individual results vary. This page is information, not a substitute for medical advice.

Is Mounjaro, or Ozempic, a tier 3 or tier 4 drug? Tiers belong to US insurance formularies, where plans sort medicines into price bands that decide what a patient pays. The UK does not use that system. Here, the questions that matter are whether a medicine is prescription-only, who may prescribe it, and whether the NHS funds it for a given patient.

Likewise, a schedule is the kind of label used for controlled substances. Mounjaro is prescription-only, and the SmPC and leaflet are the place for formal regulatory detail¹¹³.

Prescription-only status has practical consequences for you:

• You cannot legitimately buy it without a consultation and prescription.
• A prescriber decides whether it is suitable and at what dose.
• Repeat orders re-check suitability, and nothing ships automatically.
• Genuine pens should come from a registered pharmacy; you can check ours on the GPhC register under registration 9012878.

That last point matters for safety. Counterfeit and unregulated pens are a real concern, and the MHRA publishes counterfeit medicine alerts⁷. Our supply comes through official LillyDirect, direct from Eli Lilly’s UK distribution, and we dispense genuine KwikPens. A seller that offers to supply without a consultation or prescription is a red flag, however professional its website looks.

Patent status is sometimes confused with legal classification. A patent controls who can manufacture a medicine, not who can prescribe or buy it. For that separate question, see our explainer on whether tirzepatide is patented.

In short: pharmacological class is dual agonist; legal class is prescription-only; tier is not a UK concept. Keeping those apart removes most of the confusion in this topic.

08 · Licensed uses and trial evidence

What the classification is licensed to treat

Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes. It comes as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg¹.

Licensing is separate from class. Two medicines can share a class and still have different approved uses, doses and populations. Mounjaro’s licence is the reason a prescriber can offer it for weight management when you meet the criteria. NICE guidance sets out how it should be used on the NHS for overweight and obesity⁴.

For the headline weight-management evidence, the key trial is SURMOUNT-1. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone².

These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them. Trial averages do not predict your own result. Some people lose less, some more, and the dose you settle at depends on response and tolerability, decided with your prescriber.

A worked example helps show what a percentage means in practice. For someone starting at 100 kg, 20.9% is about 21 kg.

Being a dual agonist does not make a medicine suitable for everyone. Treatment decisions rest on your BMI, health conditions and history. You should not take it if you are allergic to tirzepatide or any of its ingredients, and it should not be used during pregnancy or while trying to conceive. Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive. Your prescriber will take extra care, or may recommend against treatment, if you have a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems. Broadly, the licensed weight-management criteria use BMI thresholds of 30 kg/m², or 27 kg/m² with a weight-related condition, and a prescriber confirms whether you fit. Weight-related conditions are part of why obesity is increasingly treated as a medical condition; our blog on whether obesity is a disease explains what that classification means.

A first year at standard prices is £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg. A new customer’s first order is £40 less, and every later order is £25 less. Prices checked 10 October 2026.

09 · NHS and private access

NHS availability versus private treatment

Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions)⁴⁶.

Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting. The classification is identical either way. A pen is the same prescription-only medicine whether it is funded by the NHS or paid for privately, and the same dual GIP and GLP-1 action applies.

What differs is route and cost. NHS access depends on local rollout and whether you fall into the groups being treated at a given time. Your GP can tell you where you stand. The NHS also publishes a general guide to tirzepatide covering its use for type 2 diabetes and obesity⁵.

Private treatment suits people who meet the licensed criteria but are not yet eligible on the NHS, or who prefer not to wait. A responsible private provider should behave like a pharmacy, not a shop. That means a real consultation, review by a GPhC-registered prescriber, and an honest outcome if the medicine is not suitable for you.

• You complete a free online consultation, a short health questionnaire with no charge and no obligation.
• A GPhC-registered prescriber reviews it. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.
• Our registered pharmacy dispenses and dispatches on the same day when ordered by 3pm.
• Delivery is free, next-day, tracked and temperature-controlled. Saturday delivery is £14.99.

Monthly reviews, dose titration and follow-up assessments are part of the aftercare, and support is available Monday to Friday. Payment can be by card, Klarna or pay-monthly options, with no subscriptions. All six doses are in stock.

Treatment starts at the 2.5mg strength and steps up over a period called titration. If you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £959.96 at standard prices before discounts. You can start on the Mounjaro pen page.

None of this changes the classification. It changes how you obtain the medicine, and the right route is the one that fits your eligibility, timing and budget.

10 · Interactions and safety

Drug interactions and safety for this class

The class affects which interactions matter, because slowing stomach emptying can change how other medicines are absorbed. The most important example is oral contraception: the medicine can reduce absorption of oral contraceptives because stomach emptying slows. The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹ The MHRA has published guidance on contraception with these medicines⁷, and a prescriber will discuss what that means for you.

Diabetes medicines are the other key group. If you take insulin or a sulfonylurea, doses may need adjusting because of the risk of low blood sugar. That does not mean the medicines are forbidden together; it means your prescriber should review the plan. Always tell the prescriber about every medicine you take, including those bought over the counter.

Common side effects are mostly digestive. The most common, affecting more than 1 in 10 people, are nausea, diarrhoea, vomiting, constipation and abdominal discomfort. Side effects are most likely when starting treatment or moving up a dose, and for most people they ease within days to a few weeks. The BNF also sets out the prescribing and safety information used by clinicians¹¹.

New symptoms deserve attention. If you notice something new while on treatment, discuss it with your prescriber. You can also report suspected side effects through the MHRA Yellow Card scheme¹⁹. Reporting helps regulators monitor medicines, even for effects not yet established as linked to them.

Questions such as “what organ is Ozempic hard on?” or “can you smell when someone is on Ozempic?” come up often. The correct step is the same: read the leaflet, speak to your prescriber, and use Yellow Card if you notice something unusual.

Safety also covers where the pen comes from. Pens should be stored in the fridge at 2–8°C until first use. Once in use, a KwikPen can be kept out of the fridge at a temperature not above 30°C for up to 30 days after first use, and must then be thrown away. Unopened pens keep until the printed expiry date. For any other storage question, check the leaflet or ask the pharmacy.

Needles, a sharps bin and injection guidance are included with every order. Follow the pen’s instructions each week. If you are ever unsure about a dose, contact us before injecting rather than guessing.

11 · Myths around the class

Myths and marketing around the class

Several phrases attached to this class are marketing rather than classification. The most common is “the poor man’s Ozempic”, a label applied to low-cost supplements that claim to act like prescription medicines. It is not a pharmacological class, and these products are not in the same category as Mounjaro, Wegovy or Ozempic.

The difference is substantial. A prescription GLP-1 medicine is a licensed product with a regulated manufacturing process, a patient leaflet, a prescriber and monitoring. A supplement is a low-cost product available cheaply without assessment, with no clinical oversight and with dosing that is not standardised.

A second myth is that being in the same family means being the same medicine. Ozempic and Mounjaro both act on gut-hormone pathways, but one is a single-action GLP-1 agonist and the other is a dual GIP and GLP-1 agonist¹. Different molecules have different strengths, licences and labels, so they cannot be swapped by guesswork.

A third myth is that “the newest class” means “unregulated”. Mounjaro is a licensed prescription-only medicine. Where problems arise is in the grey market. The MHRA warns about counterfeit medicines and runs the Yellow Card scheme for reporting suspected problems⁷. If a seller promises specific results or offers to supply without a consultation or prescription, walk away.

Doses are set by a prescriber, within the licensed schedule, and any change goes through your review.

Another misunderstanding concerns the NHS. Some readers assume that because Mounjaro is a newer medicine, it is not funded at all. In fact it is available on the NHS, with access phased in over several years.

What should you trust? Start with the SmPC and leaflet, then the NHS and NICE guidance, then a prescriber who has your history in front of them. The class name is a useful starting point for understanding, not a verdict on whether a particular treatment suits you. If you want to go deeper on the active ingredient, the regulatory file and the pen, our related guides on the EPAR and pen components are a sensible next read.

12 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹